Compare ACDC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | GERN |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2021 | 1996 |
| Metric | ACDC | GERN |
|---|---|---|
| Price | $4.01 | $1.18 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $5.49 | $4.25 |
| AVG Volume (30 Days) | 1.1M | ★ 6.8M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,941,800,000.00 | $1,065,000.00 |
| Revenue This Year | $4.27 | $28.49 |
| Revenue Next Year | $9.53 | $44.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.08 | $1.04 |
| 52 Week High | $8.22 | $2.01 |
| Indicator | ACDC | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 36.90 |
| Support Level | $3.53 | $1.08 |
| Resistance Level | $5.38 | $1.26 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 12.28 | 15.00 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.